Law Professor & Assoc. Dean @URLawSchool; mom & trail hiker/runner; loves strong patent rights, legal interpretation, and good red wine
US of A
Joined November 2013
- Tweets914
- Following298
- Followers445
- Likes4K
Protecting U.S. IP from transfer to China shouldn't mean restricting American firms from acquiring and licensing foreign innovations. @USTreasury's proposed COINS Act rules risk undermining the market-driven transactions that bring valuable IP into American hands.
Kristen Osenga retweeted
Last month, 200 of the world's largest companies signed a letter to the Judicial Conference asking for mandatory disclosure of third-party funding in federal litigation.
It's no surprise that these behemoth corporations want to make it harder for small inventors to protect their intellectual property. If small inventors can't afford to defend their patents in court, corporate giants can steal their inventions with little fear of consequences.
Read IDA's newly submitted letter opposing these onerous disclosure requirements: inventorsdefense.org/wp-cont…
Multiple patents on the same medicine can protect distinct innovations. New formulations, manufacturing methods, and delivery systems can each benefit patients. A new @IPWatchdog article explains why counting patents alone tells us little about a medicine: ipwatchdog.com/2026/10/04/wh…
Medical innovation requires investment, collaboration & predictable IP protections. @EIRAInitiative's collection of one-pagers explores how strong IP supports innovation and helps new & improved medicines reach patients. Check them out here: eirainitiative.org/one-pager…
Kristen Osenga retweeted
More than 200 companies recently signed a letter advocating for federal third-party litigation funding disclosure rules.
It should come as no surprise: the same deep-pocketed companies that routinely face lawsuits are now pushing for rules that would make it harder for smaller plaintiffs -- and thousands of inventors -- to finance litigation and hold them accountable in the courtroom.
ipwatchdog.com/2026/09/15/mo…
The USPTO's fee-setting authority helps the agency plan ahead and invest in the people and technology that keep our patent system running. Congress should renew the agency's fee-setting authority before it expires. Read @Council4IP's letter on the issue: c4ip.org/wp-content/uploads/…
Strong IP protections keep the innovation cycle moving. @Council4IP's new infographic, based on Prof. Jonathan Barnett's research, shows how "idea factories" rely on patents and licensing to turn today's breakthroughs into tomorrow's innovations. c4ip.org/wp-content/uploads/…
Kristen Osenga retweeted
OPINION: “The Protecting Our Courts from Foreign Manipulation Act would make it harder for small companies to access the capital they need to defend their patent rights,” @ProfKOsenga argues.
I recently spoke with @mlexclusive about Meta's recent decision to join a video distribution patent pool. As I told MLex, this "might start showing the world that royalty free isn't free… so maybe patent pools are better." More of my thoughts here: mlex.com/mlex/articles/25017…
For decades, FRAND-based standards have helped balance broad access to technology with incentives to invent. A new blog from @IPEuropeEU explores what may be lost if established standards-development frameworks give way to mandatory "royalty-free" models: ipeurope.org/blog/the-future…
As the Senate Judiciary Committee examines the Patent Eligibility Restoration Act on Tuesday, Congress must act to restore clear patent eligibility rules. America's inventors, startups, and investors deserve a predictable legal framework that encourages innovation and investment.
My latest op-ed on patent eligibility is published at @ipwatchdog:
ipwatchdog.com/2026/07/12/su…
Kristen Osenga retweeted
Check out IDA's public comments to the International Trade Commission on its proposed disclosure rule.
inventorsdefense.org/wp-cont…
Kristen Osenga retweeted
Foreign-interference claims do not justify blanket disclosure rules. Judges can review funding arrangements privately, and CFIUS already reviews foreign investments that could pose national-security risks.
inventorsdefense.org/wp-cont…
Bad patent policy often starts with a simple mistake: assuming a problem exists without proving it. My latest @TheWellNews op-ed explains why the Medication Affordability & Patent Integrity Act risks creating new problems without solving existing ones. thewellnews.com/opinions/thi…
Kristen Osenga retweeted
Last week, the Supreme Court ruled in Hikma v. Amarin. Before the decision, Kristina Acri broke down the questions at the center of the case -- and explained why the ruling "could have a dramatic effect on incentives to invest in researching additional uses for FDA‑approved medicines." Read her analysis in @dcexaminer: buff.ly/x57IBM4
Excellent new papers from @IPPolicyInst scholars about “patent thicket” and “evergreening” claims. The collection offers an important, evidence-based look at how post-approval innovation, patent timing, and generic competition actually work in practice. unpackingip.org/ipandbiophar…
"Effective drug pricing policy should be based on empirical evidence — not unsupported patent narratives." Great new one-pager by @AdamMossoff on why strong patent rights are essential to research, investment, and innovation that improve and save lives: static1.squarespace.com/stat…
Kristen Osenga retweeted
🎙️ Check out this episode of the IP Protection Matters podcast featuring insights from @ProfKOsenga, Associate Dean for Academic Affairs at the University of Richmond School of Law.
She discusses the link between IP and innovation, patent eligibility, so-called patent "evergreening," and more.
ipprotectionmatters.org/epis…
Had a great conversation last week with @PatentGene at the @IPWatchdog Unleashed podcast. We talked about patents, IP policy, the dangers of mandatory "royalty-free" licensing -- and my career path! Listen here: youtube.com/watch?v=UiDm-zVs…